French researchers have genetically engineered a human pancreatic β-cell line that secretes insulin after stimulation with glucose or other insulin secretagogues. Transplantation of these cells into mice reversed chemically induced diabetes mellitus. Using targeted oncogenesis in human fetal tissue, Ravassard et al. have generated a unique tool for large-scale drug discovery and potentially provided a preclinical model for cell replacement therapy in diabetes mellitus.